Humasis휴마시스
205470 · KOSDAQ · ₩205470 · 휴마시스
- Market cap
- ₩59B
- Enterprise value
- −₩78B
- P/E
- —
- P/B
- 0.3×
- Dividend yield
- 0.0%
- ROE
- −7.4%
- Net margin
- −49.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−64.6% from the high
₩1,898Today: ₩2,360 – ₩2,445₩6,725
Returns
- 1W−8.6%
- 1M−8.5%
- 3M+17.8%
- 6M−40.6%
- YTD−53.1%
- 1Y−63.6%
- Volume today
- 35,454
- 0.2× the 20-day average
- Traded today
- ₩85M
- Listed shares
- 24,675,001
- EPS (12 months)
- −₩633
- Earnings yield −26.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumWeak-9.2% over the last month; the price is below its 20-day average.
- News impactLow4 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Humasis stock overview
Humasis (휴마시스, KRX: 205470) is listed on KOSDAQ, in the Biotech & Pharma sector. Humasis (a Korean company) develops and manufactures point-of-care (POCT) immunoassay reagents and in-vitro diagnostic products, including COVID-19 and HIV tests, and has been developing its own key raw materials such as antigens. Its shares closed at ₩2,380 on Oct 27, 2026, up 0.63% on the day, giving it a market value of ₩59B.
Key facts
- Market cap
- ₩59B
- Sector
- Biotech & Pharma
- Latest price change
- +0.63%
- As of
- Oct 27, 2026
- Main business
- Humasis (a Korean company) develops and manufactures point-of-care (POCT) immunoassay reagents and in-vitro diagnostic products, including COVID-19 and HIV tests, and has been developing its own key raw materials such as antigens.
Quick answers about Humasis
- What does Humasis do?
- Humasis (a Korean company) develops and manufactures point-of-care (POCT) immunoassay reagents and in-vitro diagnostic products, including COVID-19 and HIV tests, and has been developing its own key raw materials such as antigens. Through its subsidiary Billions, it produces male condoms, medical-device and mask/filter products made to strict international standards, and runs an entertainment business that plans and produces dramas, films and music and manages artists for acting, advertising and performance activities. Its diagnostic products are sold through a network of overseas specialist distributors in 11 countries, and it also supplies OEM pregnancy test kits to pharmaceutical companies in Korea.
- What is the market cap of Humasis?
- The market capitalisation of Humasis was ₩59B at the close on Oct 27, 2026.
- Who are the largest shareholders of Humasis?
- According to the latest official filings, the largest reported holders are Artist (21.33%, as of Sep 11, 2026); Incon (9.22%, as of Sep 11, 2026); Lee Myeong-heon (5.16%, as of Aug 3, 2026).
- When is the next earnings report from Humasis?
- Korean companies rarely announce results dates in advance. Based on when Humasis filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Humasis?
- Yes. The National Pension Service held 0.00% of Humasis shares as of Dec 31, 2023.
Company profile
Humasis (a Korean company) develops and manufactures point-of-care (POCT) immunoassay reagents and in-vitro diagnostic products, including COVID-19 and HIV tests, and has been developing its own key raw materials such as antigens. Through its subsidiary Billions, it produces male condoms, medical-device and mask/filter products made to strict international standards, and runs an entertainment business that plans and produces dramas, films and music and manages artists for acting, advertising and performance activities. Its diagnostic products are sold through a network of overseas specialist distributors in 11 countries, and it also supplies OEM pregnancy test kits to pharmaceutical companies in Korea.
Written by AI from the company's latest annual report.
- Korean name
- 휴마시스
- Sector
- Biotech & Pharma
- Themes
- Medical devices
- CEO
- 박우람
- Founded
- Aug 2014
- Listed
- Dec 2014
- Listed shares
- 24,675,001
- Fiscal year ends
- Month 12
- Website
- www.humasis.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Amended: Shareholders' meeting calledOct 21, 2026
- Reference Document for Proxy Solicitation of Voting RightsOct 21, 2026
- Notice of shareholders' meetingOct 21, 2026
- Amended: Shareholders' meeting calledOct 14, 2026
- Amended: Shareholders' meeting calledSep 15, 2026
Titles in Korean until English translations are added.
Also known as: Humasis / 휴마시스 / 205470 / KRX:205470
Source: KRX statistical information